Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 1:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 851 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Hormone Replacement Therapy (HRT) Clear all
Completed Phase 3 Interventional Results available

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

NCT01218659
View directory record Official record
Conditions
Fabry Disease
Interventions
migalastat hydrochloride, agalsidase
Drug · Biological
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
16 Years to 74 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Decatur, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Oct 12, 2026, 1:55 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)

NCT02781727
View directory record Official record
Conditions
Growth Hormone Deficiency, Pediatric, hGH (Human Growth Hormone), Endocrine System Diseases, Hormones, Pituitary Diseases
Interventions
Once weekly subcutaneous injection of TransCon hGH, Once daily subcutaneous injection of Genotropin
Drug
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
3 Years to 12 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 12, 2026, 1:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Implementing a Virtual Tobacco Treatment for Cancer Patients in Community Oncology Practices

NCT03808818
View directory record Official record
Conditions
Carcinoma In Situ, Current Smoker, Malignant Neoplasm, Primary Neoplasm, Recurrent Neoplasm, Smoking Cessation
Interventions
Behavioral, Psychological or Informational Intervention, Nicotine Replacement, Quality-of-Life Assessment, Survey Administration, Tobacco Cessation Counseling
Other · Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
42
States / cities
Anchorage, Alaska • Atlanta, Georgia • Augusta, Georgia + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 12, 2026, 1:55 AM EDT
Completed Phase 3 Interventional Results available

A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency

NCT03305016
View directory record Official record
Conditions
Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency, Pituitary Diseases
Interventions
TransCon hGH
Drug
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
6 Months to 17 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 12, 2026, 1:55 AM EDT
Recruiting Not applicable Interventional

rTMS Over the Dorsolateral Prefrontal Cortex for the Treatment of Impulse Control Disorders in Parkinson's Disease

NCT06237868
View directory record Official record
Conditions
Impulse Control Disorder, Parkinson Disease
Interventions
rTMS Active, rTMS Sham
Device
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 12, 2026, 1:55 AM EDT
Recruiting Not applicable Interventional

Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection

NCT05219110
View directory record Official record
Conditions
Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome
Interventions
Infusion of 200% maintenance fluids as balanced crystalloid IV solution, Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution
Other
Lead sponsor
University of Calgary
Other
Eligibility
9 Months to 21 Years
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
22
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 12, 2026, 1:55 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Development of a Mobile Health Intervention for Electronic Cigarette Use Among Young Adults

NCT06395415
View directory record Official record
Conditions
Electronic Nicotine Delivery Systems, Tobacco Products, Cigarette Smoking
Interventions
EQUIP, Standard Care
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 26 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 12, 2026, 1:55 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Primary Ovarian Insufficiency: Phenotype and Optimal Treatment

NCT03568708
View directory record Official record
Conditions
Primary Ovarian Insufficiency
Interventions
Transdermal Estrogen
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
11 Years to 18 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 12, 2026, 1:55 AM EDT
Not listed Phase 1 Interventional

A Study of Anginera In Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery

NCT00364390
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Anginera, a human tissue replacement therapy
Drug
Lead sponsor
Theregen, Inc.
Industry
Eligibility
35 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
New Haven, Connecticut • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 30, 2009 · Synced Oct 12, 2026, 1:55 AM EDT
Terminated Not applicable Interventional Results available

Analysis of Aldehyde Biomarkers of Exposure and Host Response

NCT00482690
View directory record Official record
Conditions
Smoking Cessation
Interventions
nicotine polacrilex, nicotine transdermal system, nicotine inhaler
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 12, 2026, 1:55 AM EDT
Recruiting No phase listed Observational

Von Willebrand Factor in Pregnancy (VIP) Study

NCT04146376
View directory record Official record
Conditions
Von Willebrand Diseases
Interventions
Use of a postpartum diary and additional blood draws., VWF replacement therapy with Wilate, Tranexamic acid
Other · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
11
States / cities
Aurora, Colorado • New Haven, Connecticut • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 12, 2026, 1:55 AM EDT
Completed Not applicable Interventional

Androgen Replacement Therapy in Women With Hypopituitarism

NCT00027430
View directory record Official record
Conditions
Hypopituitarism
Interventions
TheraDerm
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 12, 2026, 1:55 AM EDT
Terminated Phase 1Phase 2 Interventional

A Phase 1/2 Study of High-dose Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure

NCT02346422
View directory record Official record
Conditions
Ischemic Cardiomyopathy, Non-ischemic Cardiomyopathy, Heart Failure, Cardiomyopathies
Interventions
MYDICAR Phase 1, MYDICAR Phase 2, Placebo Phase 2 only
Genetic
Lead sponsor
Celladon Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
4
States / cities
La Jolla, California • San Diego, California • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 12, 2026, 1:55 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Tobacco and Socioeconomic Disadvantage

NCT03620708
View directory record Official record
Conditions
Tobacco Smoking
Interventions
Motivational Interviewing, Nicotine Replacement Therapy Sampling, Referral Only
Behavioral · Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 12, 2026, 1:55 AM EDT
Completed Phase 4 Interventional

Safety of Stopping Pancreatic Enzyme Replacement Therapy in Children With Improved Pancreatic Function After Highly Effective Modulator Therapy

NCT07632768
View directory record Official record
Conditions
Cystic Fibrosis (CF), Pancreatic Insufficiency, Pancreas Disease, Exocrine Pancreatic Insufficiency, Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis, CFTR Gene Mutation
Interventions
Discontinuation of Pancreatic Enzyme Replacement Therapy
Drug
Lead sponsor
Indiana University
Other
Eligibility
0 Years to 18 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 12, 2026, 1:55 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Mobile App for Smoking Cessation and Mental Health

NCT04887558
View directory record Official record
Conditions
Smoking Cessation, Mental Illness
Interventions
Smart-T Mental Health+ and NRT, QuitGuide + NRT
Combination Product
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 100 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 12, 2026, 1:55 AM EDT
Completed Not applicable Interventional Results available

Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1

NCT00142935
View directory record Official record
Conditions
HIV Prevention, Opioid-Related Disorders
Interventions
Pre-release Initiation of MMT, Post Release Initiation of MMT., Standard of Care Plus
Behavioral
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 6, 2014 · Synced Oct 12, 2026, 1:55 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Smoking Cessation Peds Asthma

NCT02640521
View directory record Official record
Conditions
Smoking Cessation, Asthma
Interventions
Chart Reminders & New York State Quit line referral system
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Oct 12, 2026, 1:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Developing Genetic Education for Smoking Cessation

NCT01186016
View directory record Official record
Conditions
Tobacco Smoking
Interventions
Genetic Education Session, Nutrition Education Session
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 12, 2026, 1:55 AM EDT
Completed Phase 2 Interventional Results available

Combination Bupropion / Varenicline for Smoking Cessation in Male Smokers

NCT01806779
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Chantix, Zyban, Nicotine patches
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Charlotte, North Carolina • Durham, North Carolina • Raleigh, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Oct 12, 2026, 1:55 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Kronos Early Estrogen Prevention Study (KEEPS)

NCT00154180
View directory record Official record
Conditions
Menopause, Arteriosclerosis
Interventions
Conjugated equine estrogens 0.45 mg/day, Transdermal estradiol, 50 mcg/day, Micronized progesterone, 200 mg/day x 12 d/month, CEE , progesterone, estradiol patch or placebo for each, CEE, progesterone, transdermal patch or the placebo
Drug
Lead sponsor
Kronos Longevity Research Institute
Other
Eligibility
42 Years to 58 Years · Female only
Enrollment
728 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
9
States / cities
Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2009 · Synced Oct 12, 2026, 1:55 AM EDT
Not listed Phase 1Phase 2 Interventional

A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy

NCT04445220
View directory record Official record
Conditions
COVID-19, Acute Kidney Injury, Sepsis
Interventions
SBI-101
Biological
Lead sponsor
Sentien Biotechnologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Albuquerque, New Mexico • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 12, 2026, 1:55 AM EDT
Terminated Phase 4 Interventional Results available

TOM: Testosterone in Older Men With Sarcopenia

NCT00240981
View directory record Official record
Conditions
Sarcopenia, Hypogonadism, Muscular Diseases
Interventions
Topical testosterone gel 1% (active formulation), Topical gel (placebo formulation)
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
65 Years and older · Male only
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 12, 2026, 1:55 AM EDT
Completed Not applicable Interventional Results available

Pilot Testing a Digital Intervention to Improve Smoking Cessation in Persons With Serious Mental Illness

NCT04367506
View directory record Official record
Conditions
Tobacco Cessation
Interventions
BecomeAnEX, Usual Care
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 12, 2026, 1:55 AM EDT